Acme United Remains Discounted Even As Shares Move Higher

Acme United Corporation remains a solid 'Buy' as shares have outperformed the S&P 500, rising 15.5% since November. ACU's Q1 2026 revenue rose to $52.3 million, driven by the My Medic acquisition and robust organic growth, especially in Europe and Canada. Despite top-line growth, ACU's net income fell from $1.7 million to $1 million, pressured by tariffs and inventory build-up amid geopolitical uncertainty.